Gilead Sciences Inc. has announced a strategic partnership with the Global Fund to Fight AIDS, Tuberculosis and Malaria to accelerate access to lenacapavir, a twice-yearly injectable HIV-1 capsid inhibitor, for HIV prevention in primarily low- and lower-middle-income countries. This agreement will enable Gilead to supply the medicine to up to two million people over three years at no profit, while awaiting the availability of licensed generic versions. The European Medicines Agency has validated Gilead's application for lenacapavir under the EU-M4all procedure, which could expedite regulatory reviews in resource-limited countries. Gilead is actively collaborating with global aid organizations to ensure timely distribution and is pursuing strategies to support access in middle-income countries not covered by this agreement.